Seres Therapeutics, Inc. (MCRB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d100733dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 S ERES T HERAPEUTICS , I NC . 2025 I NCENTIVE A WARD P LAN ( AS AMENDED AND RESTATED EFFECTIVE July 8, 2026) I. P URPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who mak
How this was made
The 30-second read
Why it matters
This is primarily an equity compensation and governance document. Traders may monitor it for changes to share limits, director compensation caps, and any disclosed officer/director changes, but the excerpt does not provide new clinical or financial datapoints.
Market read
Potentially relevant for dilution and retention expectations, but the excerpt is mostly plan mechanics without quantified incremental impact.
What to watch
The provided excerpt does not include the full 8-K details on specific director/officer departures, elections, or actual award grants, which could be more market-relevant than the plan boilerplate.
Background
The SEC 8-K reports Item 5.02 and Item 5.07, including an incentive award plan amendment and restatement effective July 8, 2026.
Ticker impact
Seres Therapeutics filed an 8-K amending and restating its 2025 Incentive Award Plan effective July 8, 2026, covering director/officer compensation.
Low likelihood of a sustained price move solely from this plan amendment; any impact would be indirect via perceived dilution/retention effects.
The excerpt is primarily plan mechanics (share limits, eligibility, director compensation cap) rather than new financial guidance, clinical results, or a transaction. Such filings can move the stock modestly if investors focus on dilution, but the text provided does not quantify incremental share issuance or specific grants.
Market effects
Routine equity-compensation plan updates are common in biotech and typically do not change sector fundamentals.
None indicated.
None indicated.
Counterpoint
If the amended plan materially increases the share pool or director/officer compensation flexibility, the market could reprice dilution risk even without new operating results.
Key entities
- issuerSeres Therapeutics, Inc.
Subject of the SEC 8-K, including an amended and restated 2025 Incentive Award Plan effective July 8, 2026.
- equity_compensation_plan2025 Incentive Award Plan (as amended and restated)
Defines eligibility, share availability, recycling mechanics, and non-employee director compensation limits.
